OGN Stock Price, Chart, Stats & News

Organon & Co.
Save
OGN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 53.59% |
Operating margin | 20.01% |
Pretax margin | 6.84% |
Net margin | 3.01% |
Effective tax rate | 56.00% |
ROA | 1.45% |
ROE | 25.50% |
D/E | 11.70x |
Interest coverage ratio | 2.46x |
OGN valuation
P/E | 14.41x |
P/S | 0.24x |
P/B | 2.02x |
P/CF | 2.17x |
P/FCF | 3.76x |
P/OCF | 2.17x |
PEG | -0.13x |
EV multiple | -5.16x |
About
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio).
Similar securities
Based on sector and market capitalization
Report issue











